Abcam, ab187091, Anti-MLKL (phospho S358) antibody [EPR9514]

Size: 20µL / 100µL / 1mL
Anti-MLKL (phospho S358) antibody [EPR9514] (ab187091) is a rabbit monoclonal antibody detecting MLKL in Western Blot, IHC-P, Dot Blot . Suitable for Human . - Biophysical QC for unrivalled batch-batch consistency - Over 210 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR9514,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, WB, DotSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Stimulation may be required to allow detection of the phosphorylated protein. Please see images below for recommended treatment conditions and positive controls.FURTHER INFORMATION ON SPECIFICITY (Chinese Version) available under the product protocols section. This file includes key technical notes of experience when using this product.

Product details:
Anti-MLKL (phospho S358) antibody [EPR9514] (ab187091) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Dot Blot, IHC-P and WB.
Anti-MLKL (phospho S358) antibody [EPR9514] (ab187091) was first used in a scientific publication in 2012 and has been cited over 216 times in peer reviewed journals. It's performance in Western Blot in human samples is trusted by the scientific community.
Abcam's high quality manufacturing and validation processes ensure Anti-MLKL (phospho S358) antibody [EPR9514] (ab187091) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-MLKL (phospho S358) antibody [EPR9514] (ab187091) has 17 independent reviews from customers.
Anti-MLKL (phospho S358) antibody [EPR9514] (ab187091) specifically detects MLKL Phospho-S358 (UniProt ID: Q8NB16; Molecular weight: 55kDa) and is sold in 100 µL and 1 mL selling sizes.
Conjugation-ready, carrier free format available for antibody clone EPR9514 -
ab208909
Mixed lineage kinase domain-like protein (MLKL) is a key executor of necroptosis, a form of programmed cell death and its expression is associated with both tumor suppression and promotion, depending on the cancer type. Its role in necroptosis and other cellular processes makes it a potential prognostic marker and therapeutic target in oncology.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MLKL also known as mixed lineage kinase domain-like protein plays a critical role in the process of necroptosis a form of programmed cell death. The MLKL protein has a molecular weight of approximately 54 kDa. The protein exists mainly within the cytoplasm but translocates to the plasma membrane during cell death execution. Expression of MLKL happens in various tissues indicating its wide biological importance. Phosphorylation of MLKL often referred to as p-MLKL is key to triggering its activity marking the transition from an inactive to an active state during necroptosis.
Biological function summary
The MLKL protein acts as an executioner of cell death by forming a complex that disrupts the plasma membrane integrity. This process is downstream of receptor-interacting serine/threonine-protein kinase 3 (RIPK3) which phosphorylates MLKL to form the active necrosome complex. Active MLKL oligomerizes and migrates towards the inner leaflet of the plasma membrane binding to phosphatidylinositol phosphates which assists in pore formation and cellular rupture. The ability to measure MLKL activity levels such as via MLKL ELISA kits is important for understanding necrotic processes in detailed studies.
Pathways
MLKL is integrally involved in the necroptotic pathway alongside RIPK1 and RIPK3 which are key initiators of necroptosis. Phosphorylated MLKL acts downstream of RIPK3 resulting in cell death without caspase activation distinguishing necroptosis from apoptosis. MLKL and RIPK3 are tightly linked within this pathway with MLKL phosphorylation serving as a vital event for the execution phase. The necroptosis pathway is part of larger networks including inflammatory response pathways highlighting the importance of MLKL's role beyond sheer cell death.
MLKL has been implicated in various inflammatory conditions and neurodegenerative diseases. The dysregulation of necroptosis can contribute to disorders such as inflammatory bowel disease and amyotrophic lateral sclerosis. In inflammatory bowel disease increased levels of p-MLKL might lead to excessive cell death exacerbating inflammation. Similarly in neurodegenerative disorders the harmful activation of MLKL may accelerate neuronal cell death. Key interactions with proteins like RIPK3 and RIPK1 highlight MLKL's involvement in these pathological processes making it a potential target for therapeutic intervention.